Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Multi-country Prospective Observational Study of Patients Initiating T-DXd in the First or Second Treatment Line for HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

NCT05592483 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05592483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05592483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Multi-country Prospective Observational Study of Patients Initiating T-DXd in the First or Second Treatment Line for HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Terminated
Start date
July 7, 2023
Completion date
May 29, 2024
Enrollment
78 (actual)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer